AERI - アエリ―・ファ―マシュ―ティカルズ (Aerie Pharmaceuticals Inc.) アエリ―・ファ―マシュ―ティカルズ

 AERIのチャート


 AERIの企業情報

symbol AERI
会社名 Aerie Pharmaceuticals Inc (アエリ―・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 アエリー・ファーマシューティカル(Aerie Pharmaceuticals Inc.)は臨床病期の製薬会社である。同社は緑内障及び眼の他の疾患の患者のための治療法の発見・開発・商業化に従事する。同社の製品候補には、Rhopressa(netarsudil点眼液)0.02%(Rhopressa)、Roclatan(netarsudil /ラタノプロスト点眼液)0.02%/ 0.005%(Roclatan)が含まれる。同社の製品候補は、開放隅角緑内障および高眼圧症患者の眼内圧(IOP)を下げるように設計される。そのRhopressaは1日1回の点眼薬である。Rhopressaは、IOPを低下させる生化学的標的であるRhoキナーゼ(ROCK)およびノルエピネフリントランスポーター(NET)を阻害する。そのRoclatanは、オープンアングルの緑内障患者の治療薬として処方されているRhopressaとlatanoprostの1日1回、固定用量の組み合わせである。同社はRoclatanの第III相臨床試験を実施している。   アエリ―・ファ―マシュ―ティカルズは米国の製薬会社。緑内障とその他目の疾患治療薬の発見、開発、商業化を行う。緑内障と高眼圧症向けに一日一回投薬で眼圧を下げるRhoキナ―ゼ阻害剤「ロ―プレッサ」と「ロクラタン」の第3相治験を行う。また、第2世代のRhoキナ―ゼ阻害剤が臨床前段階。本社はカリフォルニア州。   Aerie Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye. Its products include Rhopressa, Roclatan, AR-13503, and AR-1105. The company was founded by David L. Epstein, Casey C. Kopczynski, Thomas J. van Haarlem, and Eric J. Toone on June 22, 2005 and is headquartered in Durham, NC.
本社所在地 4301 Emperor Boulevard Suite 400 Durham CA 27703 USA
代表者氏名 Vicente Anido ヴィセンテ・アニード
代表者役職名 Chairman of the Board Chief Executive Officer 取締役会長兼最高経営責任者
電話番号 +1 919-313-9650
設立年月日 38504
市場名 NASDAQ National Market System
ipoyear 2013年
従業員数 160人
url www.aeriepharma.com
nasdaq_url https://www.nasdaq.com/symbol/aeri
adr_tso
EBITDA EBITDA(百万ドル) -187.08400
終値(lastsale) 54.17
時価総額(marketcap) 2449689445.01
時価総額 時価総額(百万ドル) 2406.276
売上高 売上高(百万ドル) 2.42300
企業価値(EV) 企業価値(EV)(百万ドル) 2244.172
当期純利益 当期純利益(百万ドル) -186.60800
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Aerie Pharmaceuticals Inc revenues increased from $0K to $2.4M. Net loss increased 77% to $95.7M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects General and administrative -Other increase from $22.6M to $53.3M (expense) Research and development - Other increase of 39% to $26.5M (expense).

 AERIのテクニカル分析


 AERIのニュース

   Aerie Pharmaceuticals Appoints Peter J. McDonnell, M.D., to the Company’s Board of Directors  2020/06/11 10:30:00 Business Wire
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, dry eye, retinal diseases and potentially other diseases of the eye, today announced that Peter J. McDonnell, M.D., has been appointed to the Company’s Board of Directors and will also be a member of both the Nominating and Corporate Governance
   Aerie (AERI) Up 1.9% Since Last Earnings Report: Can It Continue?  2020/06/05 15:31:59 Zacks Investment Research
Aerie (AERI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
   Aerie Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Business Update  2020/05/06 20:01:00 Business Wire
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, dry eye, retinal diseases and potentially other diseases of the eye, today reported financial results for the first quarter ended March 31, 2020 and provided a general business update, including the impact of the COVID-19 pandemic on company op
   Aerie Pharmaceuticals to Present at the Bank of America Securities 2020 Healthcare Conference  2020/05/05 11:30:00 Business Wire
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, dry eye, retinal diseases and other diseases of the eye today announced that Vicente Anido, Jr., Ph.D., Chairman and Chief Executive Officer, will present in a fireside discussion at the Bank of America Securities 2020 Healthcare Conference on
   Aerie Pharmaceuticals to Announce First Quarter 2020 Financial Results and Host Conference Call on Wednesday, May 6, 2020  2020/04/29 11:30:00 Business Wire
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, dry eye, retinal diseases and other diseases of the eye announced today that its first quarter 2020 financial results will be released after the market closes on Wednesday, May 6, 2020. Following the release, the Company will host a live confer
   Aerie Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Business Update  2020/05/06 20:01:00 Business Wire
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, dry eye, retinal diseases and potentially other diseases of the eye, today reported financial results for the first quarter ended March 31, 2020 and provided a general business update, including the impact of the COVID-19 pandemic on company op
   Aerie Pharmaceuticals to Present at the Bank of America Securities 2020 Healthcare Conference  2020/05/05 11:30:00 Business Wire
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, dry eye, retinal diseases and other diseases of the eye today announced that Vicente Anido, Jr., Ph.D., Chairman and Chief Executive Officer, will present in a fireside discussion at the Bank of America Securities 2020 Healthcare Conference on
   Aerie Pharmaceuticals to Announce First Quarter 2020 Financial Results and Host Conference Call on Wednesday, May 6, 2020  2020/04/29 11:30:00 Business Wire
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, dry eye, retinal diseases and other diseases of the eye announced today that its first quarter 2020 financial results will be released after the market closes on Wednesday, May 6, 2020. Following the release, the Company will host a live confer
   Aerie Pharmaceuticals (AERI) Expected to Beat Earnings Estimates: Should You Buy?  2020/04/28 16:34:00 Zacks Investment Research
Aerie (AERI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
   Aerie (AERI) Suspends Guidance Due to Coronavirus Outbreak  2020/04/13 09:01:00 Zacks Investment Research
Aerie (AERI) suspends annual guidance as volumes get impacted due to the COVID-19 outbreak.
   Aerie Pharmaceuticals to Announce First Quarter 2020 Financial Results and Host Conference Call on Wednesday, May 6, 2020  2020/04/29 11:30:00 Business Wire
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, dry eye, retinal diseases and other diseases of the eye announced today that its first quarter 2020 financial results will be released after the market closes on Wednesday, May 6, 2020. Following the release, the Company will host a live confer
   Aerie Pharmaceuticals (AERI) Expected to Beat Earnings Estimates: Should You Buy?  2020/04/28 16:34:00 Zacks Investment Research
Aerie (AERI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
   Aerie (AERI) Suspends Guidance Due to Coronavirus Outbreak  2020/04/13 09:01:00 Zacks Investment Research
Aerie (AERI) suspends annual guidance as volumes get impacted due to the COVID-19 outbreak.
   Aerie Pharmaceuticals Provides 2020 Company and Guidance Update Associated with COVID-19  2020/04/09 20:01:00 Business Wire
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, dry eye, retinal diseases and other diseases of the eye today provided a business update associated with the impact of the global Coronavirus disease (COVID-19) pandemic on Company operations. While Aerie volumes increased in the first-quarter
   Aerie Pharmaceuticals to Present at the Needham Virtual Healthcare Conference  2020/04/07 11:30:00 Business Wire
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, dry eye, retinal diseases and other diseases of the eye today announced that Vicente Anido, Jr., Ph.D., Chairman and Chief Executive Officer, will present in a fireside discussion at the Needham Virtual Healthcare Conference on Tuesday, April 1

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 アエリ―・ファ―マシュ―ティカルズ AERI Aerie Pharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)